Form 4: Shattuck Labs Director Trades Common Stock and Warrants

Shattuck Labs Director Clay B. Siegall reports transactions involving the acquisition of common stock and accompanying warrants through a private placement.

Summary

• Director Clay B. Siegall acquired 128,054 shares of Shattuck Labs, Inc. common stock.
• The acquisition was part of a private placement that closed on August 25, 2025.
• Siegall also acquired accompanying warrants to purchase an additional 128,054 shares of common stock.
• The combined price per share and accompanying warrant was $0.8677.
• The warrants are exercisable after the original issuance date until 30 days following the public announcement of data from the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 trials.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's investment in the company, but the details are transactional rather than performance-based.

Positives

• Director participation in a private placement indicates confidence in the company's future prospects.
• Acquisition of both stock and warrants suggests a long-term investment perspective.
• The exercise of warrants is tied to positive clinical trial data and future trial design, aligning insider incentives with company progress.

Negatives

• The transaction details are based on a private placement, which may not reflect broader market sentiment.
• The exercise of warrants is contingent on future events, introducing uncertainty.

Risks

• The exercise of warrants is dependent on the successful outcome and public announcement of Phase 1 clinical trial data for SL-325, including receptor occupancy and safety.
• The design of planned Phase 2 clinical trials also influences the warrant exercise timeline.
• The private placement involved accredited investors, and the terms may not be representative of public market offerings.

Future Outlook

The exercise of warrants is contingent upon the public announcement of data from the Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of planned Phase 2 clinical trials. This suggests that positive developments in these areas are anticipated.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving director participation in private placements and the acquisition of equity with performance-based exercise clauses, are common in the biotechnology sector. These actions often signal management's conviction in the company's pipeline and upcoming clinical milestones.

Related Party Transactions

• The transaction involves the reporting person, Clay B. Siegall, who is a Director of Shattuck Labs, Inc., acquiring securities in a private placement.

Stakeholder Impact

• Shareholders: The transaction indicates insider confidence, which could be perceived positively. However, the private placement terms are not fully public.
• Employees: Continued company progress, driven by successful clinical trials, would positively impact employee morale and job security.
• Creditors: The company's ability to advance its pipeline and potentially raise capital through such placements supports its financial stability.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325.
• Public announcement of the design of the planned Phase 2 clinical trial(s) for SL-325.
• Warrants become exercisable 30 days following the public announcement of the aforementioned clinical trial data and Phase 2 trial design.

Key Dates

Keywords

Shattuck Labs, STTK, Form 4, Insider Trading, Common Stock, Warrants, Private Placement, Clinical Trial, SL-325, Phase 1, Phase 2, Director